Associated Papers
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Papillary Thyroid Carcinoma: Correlation Between Molecular and Clinical Features.
Wang Q et al.
Molecular Diagnosis & Therapy, 2024
38896179 (PubMed )
Supplement: 40291_2024_721_MOESM1_ESM.xlsx › SNV
Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A et al.
Critical Reviews in Oncology/hematology, 2023
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2022
An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L et al.
Scientific Reports, 2022
35978072 (PubMed )
Supplement: 41598_2022_17791_MOESM3_ESM.xlsx › table
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2020
Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M et al.
Frontiers in Immunology, 2020
32256484 (PubMed )
Supplement: Table_4.XLSX › TCGA_HLAs_and_mutations
Select a paper to view details